financetom
Business
financetom
/
Business
/
Brookfield Powers Up: Eyes Major Stake In Neoen With A Bold Acquisition Bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brookfield Powers Up: Eyes Major Stake In Neoen With A Bold Acquisition Bid
May 30, 2024 9:07 AM

Brookfield Asset Management Inc , together with its institutional partners, including Brookfield Renewable Partners L.P. ( BEP ) and Temasek, through a special purpose vehicle, inked an exclusive negotiation to acquire a 53.32% shareholding in Neoen ( NOSPF ) for EUR 39.85 per share.

Brookfield has entered into exclusive negotiations with Impala, the Fonds Stratégique de Participations managed by ISALT, Cartusiai and Xavier Barbaro, and other shareholders.

Neoen ( NOSPF ) is a global renewables developer with an 8,000 megawatt portfolio of wind, solar and storage assets in operation or under construction alongside a significant 20,000 megawatts advanced pipeline of development projects, located in strategic markets, particularly in Australia, France and the Nordics. 

The acquisition price represents a 26.9% premium over the last closing price and premia of 40.3% and 43.5% over the 3 and 6-month volume-weighted average price, respectively.

Neoen’s Board, in a meeting on May 29, unanimously welcomed the proposed transaction.

The offer implies an equity value of 100% of the shares of EUR 6.1 billion ($6.6 billion). The company expects to obtain regulatory approvals by the fourth quarter of 2024 and launch a tender offer in the first quarter of 2025.

Subject to the closing of the block acquisition, Brookfield would file an all-cash mandatory tender offer for all of the remaining shares and outstanding convertible bonds in Neoen ( NOSPF ) with the intention of implementing a squeeze out.

The growth of AI and cloud computing continues to drive higher demand for renewable sources of power, as typified by Brookfield’s recent agreement to supply Microsoft Corporation ( MSFT ) with over 10,500 megawatts of renewable power, as per the company’s statement.

As of March-end, BAM had cash and cash equivalent of $2.6 billion.

Price Action: BAM shares are up 2.79% at $39.40 at the last check Thursday.

Image sourced from Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Magna Up 6.4% In US Premarket
Magna Up 6.4% In US Premarket
Nov 4, 2024
05:57 AM EDT, 11/01/2024 (MT Newswires) -- Magna (MG.TO, MGA) was at last look up 6.4% in US premarket on Friday despite reporting Q3 adjusted earnings Friday of US$1.28 per diluted share, down from $1.46 a year earlier. Analysts polled by Capital IQ expected $1.40. Sales for the quarter ended Sept. 30 were $10.28 billion, compared with $10.69 billion a...
Boeing's Striking Workers' Union Endorses Latest Offer to Raise Wages by 38%
Boeing's Striking Workers' Union Endorses Latest Offer to Raise Wages by 38%
Nov 4, 2024
05:25 AM EDT, 11/01/2024 (MT Newswires) -- Boeing Company ( BA ) reached a tentative agreement with union leaders representing 33,000 workers on strike since almost two months over wage disputes, multiple media outlets reported Thursday citing the International Association of Machinists and Aerospace Workers. If approved, the company's latest proposal will increase wages by 38% over four years and...
A. O. Smith Closes $120 Million Acquisition of Unilever's Pureit
A. O. Smith Closes $120 Million Acquisition of Unilever's Pureit
Nov 4, 2024
05:34 AM EDT, 11/01/2024 (MT Newswires) -- A. O. Smith ( AOS ) said Friday it completed its acquisition of Pureit for $120 million. Based in India, Pureit provides water purification services and was previously owned by Unilever ( UL ) . Price: 75.01, Change: -0.09, Percent Change: -0.12 ...
ESSA Pharma Shares Decline Premarket Amid Termination of Phase 2 Trial on Masofaniten, Enzalutamide Combination
ESSA Pharma Shares Decline Premarket Amid Termination of Phase 2 Trial on Masofaniten, Enzalutamide Combination
Nov 4, 2024
05:17 AM EDT, 11/01/2024 (MT Newswires) -- ESSA Pharma ( EPIX ) shares were down more than 65% premarket Friday after the company said it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone. The company said in a Thursday statement that the trial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved